About Us
Locus Biosciences is a precision medicine company that is developing bacteriophage products that remove disease-causing pathogenic bacteria from the human body
A new approach is desperately needed to fight antibiotic resistance.
Antibiotics were the wonder drugs of the 20th century, dramatically reducing the burden of bacterial infections on human health. This, however, created a reliance on broad-spectrum drugs that indiscriminately remove bacteria from the body despite only one species of bacteria being the culprit in a typical infection. In recent decades, bacteria have evolved resistance to nearly all commonly used antibiotics, threatening the progress that we have made and increasing the risks involved with common medical procedures from knee replacements to childbirth.
Along the way, we have learned that many bacteria contribute positively to human health and should be maintained in the body. Broad-spectrum antibiotics disrupt the normal balance of the microbiome, often leading to serious side effects or secondary problems such as C. difficile infections.
At Locus Biosciences we are on a mission to change the future of medicine by developing precision medicines that target only the pathogenic bacteria causing an infection, leaving the other bacteria in the microbiome unaffected. In parallel, we are developing biotherapeutics that leverage the microbiome to treat common diseases such as inflammatory bowel disease and cancer.
Meet the Team
We have assembled an experienced team of leaders in precision antibacterial drug development to drive our products into clinical development.
Paul is the CEO, Chairman of the Board, and Co-founder of Locus Biosciences. With a career spanning manufacturing, R&D, information technology, and corporate transformation, Paul brings broad experience to deliver on the Locus vision. Prior to Locus, Paul served as Chief Technology Officer at Patheon Pharmaceuticals and held the role of Global Head of Operations for Patheon’s Pharmaceutical Development Services business unit. He previously served as Global Head of Manufacturing and Chief Information Officer at Valeant Pharmaceuticals, among other roles. Paul was a Visiting Professor at North Carolina State University’s Poole College of Management and volunteered as an executivein-residence for the HiTEC Graduate Program, NCSU’s Entrepreneurship Collaborative, where he identified the technology that would form the basis for Locus. Paul earned a BSBA in Management Information Systems from the University of Arizona and completed the Advanced Management Program at Harvard Business School.
Paul is the Chief Development Officer of Locus Biosciences, bringing over 17 years of pharma/biotech experience in drug development and commercialization. He has deep expertise in project and portfolio management, leading cross-functional asset development teams through all phases of drug development, including several global regulatory submissions. Paul has worked with both large and small organizations and has helped manage periods of significant growth and change. He formerly served as Vice President of Program Management at Puma Biotechnology, where he provided oversight for NDA and MAA regulatory submissions and led the build-out of Puma’s commercialization business systems infrastructure ahead of their first product launch. Paul received a bachelor’s degree in Biology and Genetics from the University of British Columbia and his graduate degree in Cellular and Molecular Pathology, specializing in neuropathology, from Vanderbilt University.
Joseph is Chief Financial Officer for Locus. Before joining the company in 2017, he led the investment team at the North Carolina Biotechnology Center, directing investments in more than 60 early-stage life science companies. Joseph previously held business development and licensing roles at Novartis and Alkermes, served as Product Manager for a venture-backed bioinformatics start-up, and helped launch five start-up companies at the Cleveland Clinic. Joseph earned a BS in Biology from Case Western Reserve University and an MBA from Harvard Business School.
Nick is Chief Technology Officer at Locus Biosciences. As co-founder of EpiBiome, a San Francisco-based, venture-backed biotech company acquired by Locus, Nick brings deep experience in next-generation sequencing, high-throughput automation, and advanced manufacturing technologies. He developed Locus’s platform phage manufacturing process, used to generate drug product for the world’s first clinical trial testing a recombinant bacteriophage therapy. Nick earned his PhD in Chemistry from Stanford University, where he also completed a postdoc in developmental biology.
Jamie leads Clinical Operations and CMC Operations for Locus Biosciences, focused on the operational delivery of patient-centric Phase 1–4 clinical studies through clinical service partnerships and providers. Prior to joining Locus, he spent 18+ years at UCB in multiple leadership positions, including Global Head of Clinical Project Management and Global Head of Outsourcing, Contracts, and Strategic Partnerships, leading teams across the US, Europe, and Asia. Jamie has held clinical development positions at a sponsor, a contract research organization, and in academia, giving him a well-rounded approach to operational execution. Jamie received a BS and MA from the University of Alabama and an MPA from Louisiana State University.
Ashley leads Locus’s Program Management Office and Human Resources, responsible for the delivery of drug development programs and internal projects — including the build of the company’s award-winning viral vector manufacturing facility — along with talent acquisition and retention. Prior to Locus, Ashley worked as a Program Manager at the Duke Human Vaccine Institute, managing cross-functional teams to deliver government- and institute-funded research programs. Ashley earned her PhD in Immunology from Duke University and her MBA from the Fuqua School of Business at Duke University
Tamara brings over two decades of experience in process development, analytical development, manufacturing sciences, and technical operations in cell and gene therapies and biologics. Prior to Locus, she developed and drove manufacturing strategies that advanced products into clinical development and through registrational trials in leadership roles at Editas Medicine and Argos Therapeutics. Tamara received a BS in Chemical Engineering from the University of Arizona and an MS in Biological Engineering from North Carolina State University.
Paul has been a member of multiple Executive Management teams at both publicly traded multi-national corporations and successful startups. He currently serves as CEO of Locus Biosciences, an emerging biotech focused on discovering and developing a novel class of CRISPR/Cas antimicrobials. Paul also serves as Vice President of the Friends Board at the North Carolina Museum of Natural Sciences and as a Visiting Professor at NC State’s Poole College of Management, where he serves as an executive-in-residence for the HiTEC Graduate Program.
Bary is an Operating Partner with Cressey & Company, a private investment firm focused exclusively on investing in and building leading healthcare businesses. Prior to joining Cressey, he served as Chief Financial Officer of AMN Healthcare Services and, before that, as CFO of Valeant Pharmaceuticals International. Bary has also held executive roles at PacifiCare Health Systems (overseeing Pharmacy Benefit Management and Information Technology), Premier Inc., Tenet Healthcare, and Arthur Andersen & Co., and has served as a director on several public and private company boards.
Austin is a Partner with ARTIS Ventures, where he invests in biotech, software, and frontier technology with a focus on enterprise and health. He is a board observer at Locus Biosciences and previously served as a board director at Stringify and a board observer at Looksharp. Before ARTIS, he advised institutional investors in the secondary market for private company shares and held positions in product management and growth marketing across several technology sectors. He has been quoted in The New York Times, The Wall Street Journal, The Washington Post, Bloomberg BusinessWeek, and Inc. Austin received a Bachelor of Arts in Communication Studies from the University of Tennessee and holds FINRA Series 62, 63, 65 licenses.
Nancy is Principal, New Company Creation at Johnson & Johnson, supporting equity investments and the creation and launch of new companies aligned with J&J’s strategic business needs. She previously led transactions for the Cardiovascular, Metabolism & Retina Therapeutic Area, including the license agreement with MeiraGTx and the collaboration with Bristol-Myers Squibb on milvexian, and has negotiated numerous research collaborations, royalty monetization deals, and asset spinouts. Earlier in her career, as Director of Corporate Development, she led the team responsible for the 2009 acquisition of Cougar Biotechnology.
Henry is a Partner with ARTIS Ventures, where he invests in biotech and healthcare technologies. He is a board observer at Locus Biosciences and also serves as a Board Director at Excision, Ozlo Sleep, and FIG, and as a Board Observer at Eko Health and Glyphic Bio. Prior to ARTIS, Henry incubated Spur Labs, a computational medicine startup, as a researcher in Sendhil Mullainathan’s lab at the University of Chicago. He previously worked at Quid and was a Fellow at Longitude Capital. Henry holds an MBA from the Stanford Graduate School of Business and a BA from Harvard College
Careers
We are on a mission to revolutionize the treatment of bacterial diseases. We need intelligent, open, hard-working people who thrive in a fast-paced environment to join us on our quest.
